Compare ANDG & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANDG | AVLN |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2025 | 2026 |
| Metric | ANDG | AVLN |
|---|---|---|
| Price | $66.70 | $30.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $61.29 | ★ $61.80 |
| AVG Volume (30 Days) | 411.5K | ★ 422.0K |
| Earning Date | 11-12-2026 | 11-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $838,692,000.00 | N/A |
| Revenue This Year | $18.38 | N/A |
| Revenue Next Year | $18.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.64 | N/A |
| 52 Week Low | $18.12 | $22.24 |
| 52 Week High | $68.41 | $40.17 |
| Indicator | ANDG | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 67.64 | 59.75 |
| Support Level | $52.10 | $25.86 |
| Resistance Level | $68.41 | $33.32 |
| Average True Range (ATR) | 2.53 | 2.03 |
| MACD | -0.14 | 0.77 |
| Stochastic Oscillator | 73.93 | 76.45 |
Andersen Group Inc is a provider of independent tax, valuation, and financial advisory services to individuals and family offices, businesses, and institutional clients in the United States. It has strategically expanded its business to build an integrated platform of service offerings that enables the company to solve its clients' complex tax and financial challenges. The company's end-to-end services offerings include: Private Client Services, Business Tax Services, Alternative Investment Funds, and Valuation Services. The firm generates the key revenue from Private Client Services, which provide comprehensive tax and financial services for individuals and families, addressing complex client matters involving multigenerational wealth, charitable giving, and trust and estate planning.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.